Shionogi will pay BioVersys $6.3 million for developing BV500, BioVersys's drug candidate for non-tuberculous mycobacteria.

The lab's 25 or so full-time employees were put on administrative leave on March 27, forcing it to shut down operations.

However, infectious diseases that were hitherto under control are re-emerging globally and the pathogens of these diseases are highly resistant to known antibiotics.

The Centers for Disease Control and Prevention (CDC) reinstated more than 400 employees who had previously been laid off, the ...

Global efforts to protect children against diseases including measles, polio and tuberculosis have stalled since 2010, ...

Note that some links may require registration or subscription. Ahead of a 2-day meeting of the Advisory Committee on ...

Agency tells court that states are not suffering "irreparable harm" from cuts even as agency leaders lament "operational disruptions" and "loss of expertise and capacity." ...

The US Department of Health and Human Services is reinstating more than 450 employees at the US Centers for Disease Control ...

An estimated 200 of the reinstated workers are based in the CDC's National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention, HHS officials confirmed. Staffers at a CDC lab that does ...

There were 10,347 TB cases reported in the U.S. in 2024, or three cases per 100,000 people, according to preliminary CDC data. That's about 8% more cases than in 2023, when cases rose to above pre ...

There were 10,347 TB cases reported in the U.S. in 2024, or 3 cases per 100,000 people, according to preliminary CDC data. That’s about 8% more cases than in 2023, when cases rose to above pre ...

Outbreaks in several states have contributed to recent TB trends, including a recent one in the Kansas City, Kansas area. The Kansas TB rate jumped 148% last year, according to the new CDC data.